Omnicell (NASDAQ:OMCL) Hits New 1-Year High – What’s Next?

Omnicell, Inc. (NASDAQ:OMCL) hit a new 52-week high on Wednesday . The company traded as high as $47.79 and last traded at $47.4350, with a volume of 110807 shares changing hands. The stock had previously closed at $47.07.

Wall Street Analyst Weigh In

OMCL has been the subject of several recent research reports. Benchmark boosted their price target on Omnicell from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Zacks Research lowered Omnicell from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 9th. Wells Fargo & Company boosted their target price on shares of Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a research report on Monday. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Omnicell in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $45.40.

Omnicell Stock Up 1.1%

The stock’s 50-day moving average price is $40.02 and its two-hundred day moving average price is $33.88. The stock has a market capitalization of $2.14 billion, a P/E ratio of 111.02, a P/E/G ratio of 4.84 and a beta of 0.77. The company has a current ratio of 1.44, a quick ratio of 1.21 and a debt-to-equity ratio of 0.14.

Hedge Funds Weigh In On Omnicell

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. purchased a new position in Omnicell in the 2nd quarter worth approximately $26,000. First Horizon Corp bought a new position in Omnicell during the 3rd quarter valued at approximately $31,000. Farther Finance Advisors LLC lifted its holdings in Omnicell by 784.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company’s stock worth $36,000 after buying an additional 1,036 shares during the period. GAMMA Investing LLC grew its position in shares of Omnicell by 37.1% in the 2nd quarter. GAMMA Investing LLC now owns 1,694 shares of the company’s stock worth $50,000 after buying an additional 458 shares during the last quarter. Finally, LSV Asset Management purchased a new position in shares of Omnicell during the third quarter valued at approximately $97,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.